Standard-of-care regimens for pancreatic ductal adenocarcinoma (PDAC) include a combination of chemotherapies, which are associated with toxicity and eventually tumor resistance. The lack of relevant tool to identify and evaluate new therapies in PDAC necessitates the search for a model, especially for cases with treatment resistance to standard of care. In the study from Peschke et al (2022), they describe a longitudinal platform to identify drug-induced vulnerabilities following standard-of-care chemotherapy treatment using patient-derived organoids (PDOs) providing an opportunity to predict therapeutic response and define new treatment vulnerability induced by standard of care. Previously, tumor resistance to chemotherapy has typically been described as selection for resistant tumor cell populations. However, Peschke et al (2022) demonstrated that PDAC cells seemed to acquire resistance not only through genetic changes, but also through modifications in cellular plasticity leading to gene expression and metabolism changes. Thus, the study supports this type of platform for the identification of new therapeutic targets following standard-of-care treatments in PDAC.

中文翻译：

---

源自患者的类器官，为胰腺癌患者创造了新的机会之窗。

胰腺导管腺癌 (PDAC) 的标准护理方案包括化学疗法的组合，这与毒性和最终的肿瘤耐药性有关。由于缺乏相关工具来识别和评估 PDAC 中的新疗法，因此需要寻找一种模型，特别是对于治疗对护理标准有抵抗力的病例。在 Peschke 等人 (2022) 的研究中，他们描述了一个纵向平台，用于在使用患者衍生的类器官 (PDO) 进行标准护理化疗后识别药物引起的脆弱性，从而为预测治疗反应和定义新的治疗脆弱性提供机会由护理标准引起。以前，肿瘤对化疗的耐药性通常被描述为对耐药性肿瘤细胞群的选择。然而，Peschke 等人 (2022) 证明，PDAC 细胞似乎不仅通过遗传变化获得抗性，还通过导致基因表达和代谢变化的细胞可塑性改变获得抗性。因此，该研究支持这种类型的平台，用于在 PDAC 的标准护理治疗后识别新的治疗靶点。